Participant Flow



* 1 participant was not included in the primary analysis because they were monitored for less than 4 hours.

Baseline Characteristics

Table summarising the baseline demographic and clinical characteristics of the study participants

Characteristics	**Number of participants, n/N (%)**
Age (years, median (Q1:Q3))	77 (67:86)
Male gender	12/26 (46.2)
Ethnicity	
• British	24/26 (92.3)
• Any other white background	1/26 (3.9)
• White and Black Caribbean	1/26 (3.9)
Clinical presentation	
• Breathlessness	13/26 (50)
• Limb swelling	8/26 (30.8)
• Acute functional decline	6/26 (23.1)
• Fever	5/26 (19.2)
• Confusion/disorientation	3/26 (11.5)
• Pain	2/26 (7.7)
• Delirium	1/26 (3.9)
• Fall	1/26 (3.9)
• None of the above	3/26 (11.5)
Past Medical History	

• Heart failure	12/26 (46.2)
• Chronic kidney disease	9/26 (34.6)
• Diabetes	6/26 (23.1)
• Chronic obstructive pulmonary disease	5/26 (19.2)
• Cancer	5/26 (19.2)
• Dementia	4/26 (15.4)
• Obesity	2/26 (7.7)
• None of the above	3/26 (11.5)
Lacked capacity to consent to research*	11/26 (42.2)

*Consultee declarations were used in line with ethical approval

Outcome measures

Table summarising the primary and secondary outcome measures

	Outcome Measure	**Number of participants, n/N (%)**
Primary outcomes	Heart rate recorded in each 4-hour window	600/674 (89.0)
	Oxygen saturation recorded in each daytime 12-hour window	75/129 (58.1)
Secondary outcomes	Technology Acceptance Questionnaire completion	10/26 (38.5)*
	Any blood pressure recorded during the study	20/24 (83.3)
	Any temperature recorded during the study	18/24 (75)
	Respiratory rate in each 4-hour window	508/674 (75.4)

* The 11/26 (42.2%) participants who lacked capacity to consent to join the research study were not approached to complete the Technology Acceptance Questionnaire.

Adverse Events

Table of serious adverse events during the study monitoring period

Serious adverse events	**Number of participants, n/N (%)**
Inpatient hospital admission	2/26 (7.7)
Death	0/26 (0)